MLH1 and neoplasm: Although it was demonstrated that most hypermethylated regions in the MSI group with MLH1 promoter methylation were not associated with cancer progression, we found that EPDR1 hypermethylation was associated with MSI, node status, tumor AJCC stage, and better prognosis in CRC patients.